Am­gen spin­out Kezar hits PhII hur­dle, all eyes on June read­out for drug’s oth­er study

A 2015 spin­out from Am­gen’s $10.4 bil­lion Onyx Phar­ma­ceu­ti­cals pur­chase has hit a mid-stage road­block.

Kezar Life Sci­ences’ lead as­set, ze­tomip­zomib, showed no dif­fer­en­ti­a­tion from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER